KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Acquisitions & Divestments (2016 - 2025)

Acadia Pharmaceuticals has reported Change in Acquisitions & Divestments over the past 16 years, most recently at $105.8 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $105.8 million for Q4 2025, down 5.45% from a year ago — trailing twelve months through Dec 2025 was $493.5 million (up 50.21% YoY), and the annual figure for FY2025 was $493.5 million, up 50.21%.
  • Change in Acquisitions & Divestments for Q4 2025 was $105.8 million at Acadia Pharmaceuticals, down from $125.6 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for ACAD hit a ceiling of $259.4 million in Q1 2023 and a floor of $7.5 million in Q2 2023.
  • Median Change in Acquisitions & Divestments over the past 5 years was $104.8 million (2023), compared with a mean of $105.6 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: plummeted 89.22% in 2023 and later skyrocketed 986.67% in 2024.
  • Acadia Pharmaceuticals' Change in Acquisitions & Divestments stood at $110.5 million in 2021, then plummeted by 31.4% to $75.8 million in 2022, then skyrocketed by 36.89% to $103.8 million in 2023, then increased by 7.8% to $111.8 million in 2024, then dropped by 5.45% to $105.8 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $105.8 million (Q4 2025), $125.6 million (Q3 2025), and $131.4 million (Q2 2025) per Business Quant data.